As­traZeneca ex­pands its block­buster Imfinzi fran­chise with new ap­proval in bil­iary tract can­cer

Dubbed the first im­munother­a­py for pa­tients with ad­vanced bil­iary tract can­cer — the FDA on Fri­day ap­proved As­traZeneca’s PD-L1 Imfinzi in com­bo with gem­c­itabine and cis­platin …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER